PTCT
PTC THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$65.37
−3.87%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- $0.29
- Revenue estimate
- $303.9M
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- $0.92
- EPS estimate
- $0.24
- Revenue actual
- $360.5M
- Revenue estimate
- $298.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -48.9%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $110
- PT range
- $85 – $130
- Analysts
- 6
5 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | $0.24 | $0.92 | Beat 289.34% | $360.5M |
| May 7, 2026 | -$0.45 | -$0.03 | Beat 93.33% | $272.6M |
| Feb 19, 2026 | -$0.21 | -$1.67 | Miss -695.24% | $164.7M |
| Nov 4, 2025 | -$1.19 | $0.20 | Beat 116.81% | $211.0M |
| Aug 7, 2025 | -$1.07 | -$0.83 | Beat 22.43% | $178.9M |
| Feb 27, 2025 | -$1.12 | -$0.24 | Beat 78.57% | $213.2M |
| Nov 7, 2024 | -$1.54 | -$1.39 | Beat 9.74% | $196.8M |
| Aug 8, 2024 | -$1.00 | -$1.16 | Miss -16.00% | $186.7M |
| Apr 25, 2024 | -$1.21 | -$1.20 | Beat 0.83% | $210.1M |
| Feb 29, 2024 | $0.29 | -$0.24 | Miss -182.76% | $307.1M |
| Oct 26, 2023 | -$0.85 | -$1.76 | Miss -107.06% | $196.6M |
| Aug 3, 2023 | -$1.58 | -$2.66 | Miss -68.35% | $213.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026